IRVINE, Calif., April 24, 2015 /PRNewswire/ -- ALPHAEON Corporation announced today that they completed enrollment of two pivotal studies with their Botulinum toxin Type A neuromodulator, EVOLUS™, for the treatment of glabellar lines. Completing enrollment marks a significant milestone for the Phase III development program. Recruitment for the two U.S.-based studies began on January 2015 and was completed in March.
"We have been fortunate to partner with some of the top dermatologists and plastic surgeons in our clinical studies. Their research experience and clinical acumen was evident during this important enrollment phase of our pivotal trials," said Chris Marmo, Ph.D., President of ALPHAEON Beauty.
ALPHAEON acquired the exclusive U.S. and certain international distribution rights to the neuromodulator as part of its acquisition of Evolus Inc. in October of 2013.
About ALPHAEON Corporation
ALPHAEON Corporation is the first social commerce company transforming self-pay healthcare by bringing to market highly innovative products and services to promote consumer wellness, beauty and performance. The company works in partnership with board certified physicians ensuring access to leading advancements in lifestyle healthcare. For more information, please visit www.alphaeon.com.
Jenna Mons, Senior Vice President of Marketing and Communications
Email: [email protected]
ALPHAEON® is a registered trademark of ALPHAEON Corporation
EVOLUS™ is a trademark of ALPHAEON Corporation
SOURCE ALPHAEON Corporation